(Q37625917)

21 August 2017

1 reference

title

Mitoxantrone: benefits and risks in multiple sclerosis patients (English)

1 reference

21 August 2017

0 references

0 references

V Martinelli

1

1 reference

21 August 2017

M Radaelli

2

1 reference

21 August 2017

L Straffi

3

1 reference

21 August 2017

M Rodegher

4

1 reference

21 August 2017

G Comi

5

1 reference

21 August 2017

1 October 2009

1 reference

21 August 2017

Neurological Sciences

1 reference

21 August 2017

30 Suppl 2

1 reference

21 August 2017

S167-70

1 reference

https://scigraph.springernature.com/pub.10.1007/s10072-009-0142-7

21 August 2017

0 references

cites work

Mitoxantrone treatment of multiple sclerosis: safety considerations

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10072-009-0142-7

Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis.

21 January 2018

1 reference

12 December 2020

Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients.

1 reference

12 December 2020

Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone

1 reference

12 December 2020

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

1 reference

12 December 2020

A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis

1 reference

12 December 2020

Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis.

1 reference

12 December 2020

The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews

1 reference

12 December 2020

Management of worsening multiple sclerosis with mitoxantrone: a review

1 reference

12 December 2020

A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis

1 reference

12 December 2020

1 reference

12 December 2020

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria

1 reference

12 December 2020

Clinical pharmacology of mitoxantrone.

1 reference

12 December 2020

Acute promyelocytic leukemia following mitoxantrone as single agent for the treatment of multiple sclerosis

1 reference

12 December 2020

Mitoxantrone for multiple sclerosis

1 reference

12 December 2020

Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome

1 reference

12 December 2020

Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study

1 reference

12 December 2020

1 reference

12 December 2020

Evaluation of the myocardial performance index for early detection of mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis

1 reference

12 December 2020

10.1007/S10072-009-0142-7

Identifiers

DOI

1 reference

21 August 2017

1 reference